Association of Reported Candidate Monogenic Genes With Lung Cancer Risk

Rifkin, Andrew S.; Less, Ethan M.; Wei, Jun; Shi, Zhuqing; Zheng, Shihui; Helfand, Brian T.; Hulick, Peter J.; Krantz, Seth B.; Xu, Jianfeng

doi:10.1016/j.cllc.2023.01.005

Cited by 6 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer is characterized by the presence of thymic, lymphnode, vascular, connective, or neurogenic tumors in the lung, pleura, or mediastinum, which are caused by mutations that commonly affect epidermal growth factor receptor (EGRF), kristen rat sarcoma viral oncogene (KRAS), phosphatidylinositol-4,5-biphosphate 3kinase catalytic subunit alpha (PIK3A), and PTEN (Bironzo et al, 2022). Although the estimated heritability of these mutations is 18% (Rifkin et al, 2023), most lung cancer cases are triggered by smoking (Rustagi et al, 2023). Individuals affected by this disease present a cluster of symptoms encompassed by chest pain, fatigue, sleep deprivation, cough, dyspnea, hemoptysis, and weight loss (Ruano-Raviña et al, 2020;Luo et al, 2023).…”

Section: Lung Cancermentioning

confidence: 99%

Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives

Bravo-Vázquez,

Méndez-García,

Rodríguez

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are short (18–25 nt), non-coding, widely conserved RNA molecules responsible for regulating gene expression via sequence-specific post-transcriptional mechanisms. Since the human miRNA transcriptome regulates the expression of a number of tumor suppressors and oncogenes, its dysregulation is associated with the clinical onset of different types of cancer. Despite the fact that numerous therapeutic approaches have been designed in recent years to treat cancer, the complexity of the disease manifested by each patient has prevented the development of a highly effective disease management strategy. However, over the past decade, artificial miRNAs (i.e., anti-miRNAs and miRNA mimics) have shown promising results against various cancer types; nevertheless, their targeted delivery could be challenging. Notably, numerous reports have shown that nanotechnology-based delivery of miRNAs can greatly contribute to hindering cancer initiation and development processes, representing an innovative disease-modifying strategy against cancer. Hence, in this review, we evaluate recently developed nanotechnology-based miRNA drug delivery systems for cancer therapeutics and discuss the potential challenges and future directions, such as the promising use of plant-made nanoparticles, phytochemical-mediated modulation of miRNAs, and nanozymes.

show abstract